Comments
Shares of Cadila Healthcare hit a record high on USFDA approval.
The stock jumped as much as 9.9 per cent to a record high.
Zydus Cadila has got final approval from USFDA for Mesalamine delayed-release tablets, 1.2 g.
The product will be manufactured at Moraiya manufacturing facility in India for US market.
Lialda (mesalamine) is indicated for the treatment of mild to moderate ulcerative colitis, a chronic condition that causes inflammation in the digestive tract.
Over 3.4 million shares change hands as of 0419 GMT, thrice the average 30-day trading volume.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.